AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...

Patients with COPD had slightly more major adverse cardiovascular events after initiating single-inhaler triple therapy vs a LABA-ICS inhaler.

UK pharma major AstraZeneca’s Fasenra (benralizumab), with its highly anticipated Phase III data to be showcased at the 2025 ...

MRI of inhaled perfluoropropane can assess regional lung ventilation and monitor improvements in response to medication ...

After waking up from the procedure, he told me he could take full breaths for the first time in years,” Dr. Mark Sigler said ...

The upcoming release of Phase III Fasenra data in COPD in 2025 is expected to solidify AstraZeneca’s position in the market.

Verona Pharma stock hit a record high Thursday on continued enthusiasm for its newly launched COPD treatment, Ohtuvayre.

Cannabis dabbing, an increasingly popular way to consume highly concentrated THC, has been linked to pulmonary and neurologic ...

Dr. Moffett’s commitment to patient care and her emphasis on holistic treatment ... and COPD, promotes deeper breathing, targets mucus buildup, and provides a natural alternative to inhalers ...

Ensifentrine is a promising supplementary therapeutic option in the management of chronic obstructive pulmonary disease (COPD), according to systematic review and meta-analysis findings published in ...

Oxygen is essential to life. The respiratory system works tirelessly to provide fresh oxygen to the body and ensure that all ...

New Study Shows Promising Results for COPD Treatment Nov. 20 ... molecule is as sneaky as its inventors ... COPD and BPD: Inhalation of Live Lactobacilli Lessens Lung Inflammation and Improves ...